The firm expects to use proceeds to fund R&D efforts, including development of its next-generation molecular diagnostics system.
The company raised about $73.8 million in net proceeds, which will go toward expansion of its facilities and further development of its sequencing technology.
The company anticipates netting $64.1 million in proceeds from the offering.
The firm sold 15,686,000 shares of common stock at a price of $2.20 per share.
The firm is selling nearly 1.2 million shares at $1.99 per share in a direct offering.
Opko said it may use some of the proceeds to make additional acquisitions.
Vermillion anticipates net proceeds of $20.2 million from the offering of 4 million common shares.
The company has lowered its price target to up to $29.9 million from as much as $33.9 million.
The company said the offering is expected to close mid-February.
The firm said that the overallotment option of 2.1 million shares was exercised, resulting in net proceeds of around $90.5 million from the offering.
The Economist reports that it is increasingly easier to analyze the metabolites people give off, potentially revealing personal information about them.
A controversial paper on the gender gap in science has been corrected, according to BuzzFeed News.
The Los Angeles Times reports that only a third of California students meet the state's new science standards.
In Science this week: evidence of interbreeding between the ancestors of West Africans and an unknown archaic human, and more.